Product Description
Indicated for ALK/ROS1 mutant nonn-small cell lung cancer (Sourced from: https://www.zelgen.com/en/index.php/chanpinxian/)
Mechanisms of Action: ALK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Suzhou Zelgen
Company Location: Asia Pacific
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Phase 1: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03607188 |
NSCLC | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2022-10-17 |
12% |
2024-03-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04032821 |
ZGALK003 | P1 |
Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2019-12-16 |
88% |
2020-07-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
NCT04211922 |
ZGALK002 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2022-10-11 |
29% |
2024-04-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/10/2021 |
News Article |
Anaplastic Lymphoma Kinase ALK Inhibitors Market, 2026 |
|
07/06/2021 |
News Article |
2021 Anaplastic Lymphoma Kinase Inhibitors Pipeline Market Report - ResearchAndMarkets.com |
|
04/22/2021 |
News Article |
Worldwide Anaplastic Lymphoma Kinase ALK Inhibitors Industry to 2026 - Featuring Astellas Pharma, AstraZeneca ad Pfizer Among Others |
|
04/21/2021 |
News Article |
Insights on the Anaplastic Lymphoma Kinase ALK Inhibitors Global Market to 2026 - Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC |